Immunoliposomes

Product Details

Creative Biolabs is offering a wide range of customized immunoliposomes products with innovative liposome development platform for both academic and industrial clients.

Liposomes have been actively investigated as drug delivery vehicles. Immunoliposome is a novel method artificially prepared spherical vesicles composed of a lamellar phase lipid bilayer, which provides several diagnostic advantages by the tagged antibodies on their outer surfaces. Liposomes lack the ability to targeted delivery of drugs into a specific cell type, while immunoliposomes can achieve targeted delivery by conjugating some antibody fragments to the surface of them. These mAb fragments provide immunoliposomes to bind and internalize into the target cell with high specificity.

Our immunoliposomes can be used to develop antibody-liposomes conjugate to selectively target antigen-expressing cells, which can deliver drugs to tumor cells for improving efficacy and reducing toxicity. In addition, immunoliposomes can also be used in immunoassays and imaging. Immunoliposomes have been extensively applied in the treatment of a variety of diseases such as Alzheimer’s disease, in which immunoliposomes are conjugated to anti-transferrin receptor and anti-Aβ mAbs.

For Research Use Only. Not For Clinical Use

Technical Note

1. EDC and Sulfo-NHS must be prepared immediately prior to use and kept at room temperature. Dialysis cassettes and spin columns mustn't be used without considering their size variants. The immunoliposome solution should be dialyzed in PBS at pH 7.4. Avoid using Tris buffers due to their amine content.
2. Hydrophobic ligands or peptides are recommended to be dissolved in DMSO or DMF, with a limit of 5% of the solution. Post-conjugation, any residual DMSO or DMF should be removed using a dialysis cassette made of regenerated cellulose membrane.
3. Azides must be avoided in buffers during conjugation since they may react with DBCO. For optimum DBCO-azide reactions, use higher concentrations at warmer temperatures (up to 37°C). However, refrigerate molecules after liposome incubation to prevent their denaturation. Extending reaction times beyond the typical 12 hours can increase efficiency.
4. Conjugation of DBCO-lipid conjugated ligands post-conjugation enhances immunoliposome yield to over 80%. Also, Folate-contained liposomes target cells' folate receptors, more specifically in creating immunoliposomes with FBP-tagged antibodies/proteins or ligands.
5. DOGS-Ni-NTA lipid concentration is recommended at a maximum of 3% to prevent nonspecific binding. High imidazole's presence can inhibit binding reactions.
6. Liposomes after conjugation reactions containing excess maleimide or thiol groups can cause issues; these can be quenched with appropriate reagents. Follow an inert atmosphere during coupling to prevent oxidation of sulfhydryl, keep pH between 6.5 and 7, and use liposomes with maleimide reactive lipids for thiolated protein conjugation.
7. In assays involving liposomes coated with biotinylated ligands or peptides ensure that the strept(avidin): biotin-liposome ratio is optimized. Insufficient strept(avidin) can lead to poorly coated liposomes, resulting in lower sensitivity or specificity in assays. While size-exclusion spin columns can separate unbound ligands from liposomes, liposome adhesion to the column matrix can lead to significant loss.
8. Liposome storage should maintain a constant 4°C without any freezing circumstances to maintain their efficacy.

Publish Data

Immunoliposomes in clinical oncology: State of the art and future perspectives
Journal of controlled release
Author: Merino, M., Zalba, S., et al.

Immunoliposomes, equipped with monoclonal antibodies (mAbs) or their fragments, are designed to specifically bind to tumor-associated antigens or receptors overexpressed on cancer cells. This targeted approach enables the selective delivery of encapsulated therapeutic agents to the tumor site. Upon binding to the target cells, the immunoliposomes are internalized through receptor-mediated endocytosis, leading to their transportation to lysosomes. In the lysosomes, the liposomes degrade, releasing the encapsulated drugs into the intracellular space. The released drugs then exert their cytotoxic effects by interfering with critical cellular processes, ultimately inducing cancer cell death. This targeted delivery system offers significant advantages over traditional chemotherapy, including improved drug accumulation at the tumor site, enhanced therapeutic outcomes, and reduced adverse effects. The role of immunoliposomes in this study underscores their potential in advancing cancer therapy by providing a more precise and efficient method of drug delivery.

Fig. 1 The mechanism triggered by the complexes formed by the ligand-receptor interaction between targeted liposomes and the receptor

FAQs

Resources

For Research Use Only. Not For Clinical Use